From setbacks to success: lessons from the journey of RSV vaccine development
Respiratory syncytial virus (RSV) causes high worldwide infant mortality, as well as a high disease burden in the elderly. Efforts in vaccine development over the past 60 years have recently delivered three approved vaccines and two monoclonal antibodies (mAbs). Looking back at the eventful history...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | Therapeutic Advances in Vaccines and Immunotherapy |
| Online Access: | https://doi.org/10.1177/25151355241308305 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846115307045781504 |
|---|---|
| author | Victor M. Cnossen Rogier P. van Leeuwen Natalie I. Mazur Charlotte Vernhes Wouter ten Voorde Jacobus Burggraaf Saco J. de Visser Meta Roestenberg Ingrid M. C. Kamerling |
| author_facet | Victor M. Cnossen Rogier P. van Leeuwen Natalie I. Mazur Charlotte Vernhes Wouter ten Voorde Jacobus Burggraaf Saco J. de Visser Meta Roestenberg Ingrid M. C. Kamerling |
| author_sort | Victor M. Cnossen |
| collection | DOAJ |
| description | Respiratory syncytial virus (RSV) causes high worldwide infant mortality, as well as a high disease burden in the elderly. Efforts in vaccine development over the past 60 years have recently delivered three approved vaccines and two monoclonal antibodies (mAbs). Looking back at the eventful history of RSV vaccine development, several factors can be identified that have hampered the developmental pathway, including the occurrence of enhanced RSV disease (ERD) in the first vaccine attempt and the difficulty in characterizing and stabilizing the pre-fusion F protein as a vaccine target. Moreover, the need for large trials to test vaccine efficacy, usually done late in development, and the lack of a correlate of protection (CoP) result in significant uncertainties in RSV vaccine development. The use of controlled human infection models (CHIMs) may provide a solution for some of these problems: through swift, cost-efficient and closely monitored assessment of vaccine safety and efficacy in early clinical phases, vaccines can either ‘fail fast’ or show results supporting further investments. Moreover, CHIMs facilitate the assessment of disease and could assist in the identification of a CoP supporting late-stage development. Although some factors may affect translatability to real-world vaccine efficacy, CHIMs can support the clinical development pathway in various ways. We advocate for, and demonstrate, a conceptual and rational design of RSV vaccine development. Assessing protective efficacy early on would result in the most cost-efficient pathway and identification of target populations should be done as early as possible. For RSV, elderly individuals and people in low- and middle-income countries are high-impact populations for RSV prevention. While RSV immunization is now available in certain regions, global access is not accomplished yet, and worldwide prevention does not seem within reach. Quick and cost-effective assessments of candidates currently in the pipeline could contribute to future successes in the battle against RSV. |
| format | Article |
| id | doaj-art-861a0422eec7424a8e4d323034ddc296 |
| institution | Kabale University |
| issn | 2515-1363 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Vaccines and Immunotherapy |
| spelling | doaj-art-861a0422eec7424a8e4d323034ddc2962024-12-19T15:03:43ZengSAGE PublishingTherapeutic Advances in Vaccines and Immunotherapy2515-13632024-12-011210.1177/25151355241308305From setbacks to success: lessons from the journey of RSV vaccine developmentVictor M. CnossenRogier P. van LeeuwenNatalie I. MazurCharlotte VernhesWouter ten VoordeJacobus BurggraafSaco J. de VisserMeta RoestenbergIngrid M. C. KamerlingRespiratory syncytial virus (RSV) causes high worldwide infant mortality, as well as a high disease burden in the elderly. Efforts in vaccine development over the past 60 years have recently delivered three approved vaccines and two monoclonal antibodies (mAbs). Looking back at the eventful history of RSV vaccine development, several factors can be identified that have hampered the developmental pathway, including the occurrence of enhanced RSV disease (ERD) in the first vaccine attempt and the difficulty in characterizing and stabilizing the pre-fusion F protein as a vaccine target. Moreover, the need for large trials to test vaccine efficacy, usually done late in development, and the lack of a correlate of protection (CoP) result in significant uncertainties in RSV vaccine development. The use of controlled human infection models (CHIMs) may provide a solution for some of these problems: through swift, cost-efficient and closely monitored assessment of vaccine safety and efficacy in early clinical phases, vaccines can either ‘fail fast’ or show results supporting further investments. Moreover, CHIMs facilitate the assessment of disease and could assist in the identification of a CoP supporting late-stage development. Although some factors may affect translatability to real-world vaccine efficacy, CHIMs can support the clinical development pathway in various ways. We advocate for, and demonstrate, a conceptual and rational design of RSV vaccine development. Assessing protective efficacy early on would result in the most cost-efficient pathway and identification of target populations should be done as early as possible. For RSV, elderly individuals and people in low- and middle-income countries are high-impact populations for RSV prevention. While RSV immunization is now available in certain regions, global access is not accomplished yet, and worldwide prevention does not seem within reach. Quick and cost-effective assessments of candidates currently in the pipeline could contribute to future successes in the battle against RSV.https://doi.org/10.1177/25151355241308305 |
| spellingShingle | Victor M. Cnossen Rogier P. van Leeuwen Natalie I. Mazur Charlotte Vernhes Wouter ten Voorde Jacobus Burggraaf Saco J. de Visser Meta Roestenberg Ingrid M. C. Kamerling From setbacks to success: lessons from the journey of RSV vaccine development Therapeutic Advances in Vaccines and Immunotherapy |
| title | From setbacks to success: lessons from the journey of RSV vaccine development |
| title_full | From setbacks to success: lessons from the journey of RSV vaccine development |
| title_fullStr | From setbacks to success: lessons from the journey of RSV vaccine development |
| title_full_unstemmed | From setbacks to success: lessons from the journey of RSV vaccine development |
| title_short | From setbacks to success: lessons from the journey of RSV vaccine development |
| title_sort | from setbacks to success lessons from the journey of rsv vaccine development |
| url | https://doi.org/10.1177/25151355241308305 |
| work_keys_str_mv | AT victormcnossen fromsetbackstosuccesslessonsfromthejourneyofrsvvaccinedevelopment AT rogierpvanleeuwen fromsetbackstosuccesslessonsfromthejourneyofrsvvaccinedevelopment AT natalieimazur fromsetbackstosuccesslessonsfromthejourneyofrsvvaccinedevelopment AT charlottevernhes fromsetbackstosuccesslessonsfromthejourneyofrsvvaccinedevelopment AT woutertenvoorde fromsetbackstosuccesslessonsfromthejourneyofrsvvaccinedevelopment AT jacobusburggraaf fromsetbackstosuccesslessonsfromthejourneyofrsvvaccinedevelopment AT sacojdevisser fromsetbackstosuccesslessonsfromthejourneyofrsvvaccinedevelopment AT metaroestenberg fromsetbackstosuccesslessonsfromthejourneyofrsvvaccinedevelopment AT ingridmckamerling fromsetbackstosuccesslessonsfromthejourneyofrsvvaccinedevelopment |